Schwab Charles Investment Management Inc. bought a new stake in Lion Biotechnologies, Inc. (NASDAQ:IOVA) in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 209,132 shares of the biotechnology company’s stock, valued at approximately $1,538,000. Schwab Charles Investment Management Inc. owned 0.34% of Lion Biotechnologies at the end of the most recent reporting period.
Separately, Russell Investments Group Ltd. bought a new stake in Lion Biotechnologies during the 2nd quarter valued at $380,000. Institutional investors own 66.64% of the company’s stock.
IOVA has been the topic of several research analyst reports. Chardan Capital reaffirmed a “buy” rating on shares of Lion Biotechnologies in a report on Thursday, September 7th. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Lion Biotechnologies in a research report on Wednesday, August 16th. Zacks Investment Research upgraded shares of Lion Biotechnologies from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research report on Tuesday, July 18th. Oppenheimer Holdings, Inc. set a $13.00 target price on shares of Lion Biotechnologies and gave the stock a “buy” rating in a research report on Tuesday, October 31st. Finally, Cowen and Company reiterated a “buy” rating on shares of Lion Biotechnologies in a research report on Wednesday, August 16th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $14.53.
Shares of Lion Biotechnologies, Inc. (NASDAQ IOVA) traded up $0.20 during midday trading on Friday, reaching $8.05. 517,300 shares of the company’s stock were exchanged, compared to its average volume of 363,658. Lion Biotechnologies, Inc. has a one year low of $4.45 and a one year high of $8.60.
Lion Biotechnologies (NASDAQ:IOVA) last announced its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). equities research analysts predict that Lion Biotechnologies, Inc. will post -1.37 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This news story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2017/11/11/schwab-charles-investment-management-inc-takes-1-54-million-position-in-lion-biotechnologies-inc-iova.html.
Lion Biotechnologies Company Profile
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.